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Abstract
Background: The authors present the high-resolution computed tomography findings of an
immunosuppressed patient with semi-invasive pulmonary aspergillosis.
Case presentation: The main finding consisted of irregular, thick-walled cavity in the right upper
lobe and a mass with soft-tissue attenuation within it and thickening of adjacent pleura. Additional
findings were bronchial wall thickening associated with a 'tree-in-bud' pattern. Following the clinical,
laboratorial and imaging criteria, the diagnosis of semi-invasive pulmonary aspergillosis was defined
and antifungical treatment was introduced.
Conclusion: The patient responded well to the treatment with improvement in his systemic
symptoms and regression of the pulmonary lesions.
Background
Aspergillus is a saprophytic, aerobic fungus that develops
on dead or decaying organic matter and produces air-
borne spores that can be inhaled by man [1]. The pulmo-
nary aspergillosis manifestations are determined by the
patient's immune status and the presence of underlying
disease [2].
Pulmonary aspergilosis can be subdivided into five cate-
gories: saprophytic aspergillosis (aspergiloma), hypersen-
sitivity reaction (allergic bronchopulmonary
aspergillosis), semi-invasive (chronic necrotizing)
aspergillosis, airway-invasive aspergillosis (acute tracheo-
bronchitis, bronchiolitis, bronchopneumonia, obstruct-
ing bronchopulmonary aspergillosis), and angioinvasive
aspergillosis [2]. Semi-invasive aspergillosis, also known
as chronic necrotizing aspergillosis (CPNA) is a chronic
form, in which the fungus is intermediate between a sim-
ple saprophyte and an invasive pathogen [3]. This condi-
tion occurs predominantly in patients with some evidence
of mild systemic immunodeficiency such as chronic debil-
itating illness, immunosuppression therapy or advanced
age. Furthermore, the presence of superimposed structural
lung disease, such as chronic obstructive pulmonary dis-
ease or bronchiectasis adds an additional risk factor [3-6].
The purpose of this report is to present the radiographic
and computed tomography (CT) findings of semi-inva-
sive aspergillosis in a lupic and diabetic patient who
underwent renal transplant and subsequent immunosup-
pression therapy.
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A 24-year-old black man, presented with an one-month
history of productive cough, weight loss and malaise. He
was diagnosed to have systemic lupus erythematosus 6
years ago and he had pulmonary tuberculosis 4 years ago
and for this he received one year of antituberculosis treat-
ment. Furthermore he underwent renal transplant 3 years
ago, and developed post-transplant diabetes mellitus. He
was receiving prednisone, tacrolimus and rapamicine. He
had never smoked and there was no history of alcohol
abuse.
Physical examination showed the patient to be ill-look-
ing, emaciated, acianotic, and afebrile. Blood pressure of
100/70 mmHg, pulse rate of 80 beats per minute and res-
piratory rate of 22 breaths per minute. Laboratory tests
showed the following: hemoglobin- 9,60 g/dl, hemat-
ocrit- 30,4%, leukocytes- 8200/cu mm (49% segmented
neutrophils, band- 2%), lymphocytes- 22%. Prothrombin
time were 50% (16"1 versus 11"5 control value), Interna-
tional Normalized Ratio (INR) 1,40, partial thromboplas-
tin time (relation patient/control) were 1,50, albumin of
1,0 g/dl, urea of 99 mg/dl and creatinine of 3 mg/dl. HIV
test and Ziehl Neelsen stain for acid-fast bacili were nega-
tive. Bronchoscopy showed no abnormalities. Aspergillus
fumigatus was isolated by cultures of sputum and bron-
choalveolar lavage. Immunodiffusion tests showed no
Criptoccocus, Histoplasma or Aspergillus on blood. A pulmo-
nary biopsy was not indicated because of his hypopro-
teinemia and coagulation disturb.
The chest radiograph revealed a thick-walled cavity in the
right upper lobe with adjacent pleural thickening (Figure
1). The high-resolution computed tomography (HRCT)
showed an irregular, thick-walled cavity in the right upper
lobe and a mass with soft-tissue attenuation within it and
thickening of adjacent pleura. Additional findings were
bronchial wall thickening associated with a 'tree-in-bud'
pattern, characterizing bronchiolitis, in the right upper,
middle and lower lobes, and in the left lower lobe (Figure
2A and 2B). Along with this, a small bilateral pleural effu-
sion was seen.
He received empirical treatment for tuberculosis during
one month with no clinical response. Failure to respond
to therapy and associating the radiologic, laboratory, and
clinical findings a diagnostic of semi-invasive aspergillosis
was made, so he was started on oral voriconazole 200 mg
once every 12 hours. The patient responded well to the
treatment with improvement in his systemic symptoms
and regression of the pulmonary lesions (Figure 2C and
2D).
Discussion
CPNA is a rare locally destructive form of aspergillosis [7].
The species found most commonly in CPNA is A. fumiga-
tus [3,5,8,9], which was the fungi isolated in this case. At
histological analysis, this disease is characterized by the
presence of tissue necrosis and granulomatous inflamma-
tion [2]. The development of this form of aspergillosis
depends largely on the immune status of the patient and
the presence of superimposed structural lung disease; so
risk factors include: diabetes mellitus, chronic debilitating
illness, alcoholism, advanced age, prolonged corticoster-
oid therapy, chronic obstructive pulmonary disease, sar-
coidosis, a history of pulmonary tuberculosis, previous
resectional surgery, pneumoconiosis, collagen vascular
disease, previous radiation therapy and malnutrition. Fur-
thermore patients with chronic airflow limitation, who
are taking long term oral corticosteroids in conjunction
with recurrent courses of systemic antibiotics are also at
risk [1,4,7,10,11]. In the present case, a lupic, diabetic
patient who had a history of tuberculosis was taking
immusuppressor after renal transplantation.
The typical time course of CPNA extends over a period of
several months to years, and the clinical symptoms
include chronic cough, sputum production, fever and
constitutional symptoms such as weight loss and weak-
ness. Hemoptysis is seen in only 15% of patients
[2,3,9,10]. It is often difficult to obtain diagnostic confir-
mation of CPNA by histologic evidence of local lung tis-
sue invasion by septal hyphae, consistent with Aspergillus.
Therefore other diagnostic criteria have been proposed.
Soubani e Chandrasekar [12] have proposed the follow-
ing criteria: clinical and radiologic features consistent with
the diagnosis; isolation of Aspergillus species by culture
from sputum or from bronchoscopic or percutaneous
Chest radiograph (postero-anterior view) showing an irregu-lar, thick-walled cavity in the right upp r lobeFigure 1
Chest radiograph (postero-anterior view) showing an 
irregular, thick-walled cavity in the right upper lobe. 
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presentation, such as active tuberculosis, atypical myco-
bacterial infection, chronic cavitary histoplasmosis, or
coccidioidomycosis. The slow progression of clinical and
radiographic findings may contribute to a delay in diag-
nosis [9]. In this report, the diagnosis of CPNA was made
on the basis of clinical findings such as cough, sputum
production and constitutional symptoms associated with
radiographic appearance consistent with CPNA and the
isolation of Aspergillus from cultures of sputum and bron-
choalveolar lavage.
Radiological features include multiple nodular opacities
and areas of consolidation with or without cavitation or
adjacent pleural thickening [3,9]. It usually occurs in the
upper lobes [8]. Cavity formation is a manifestation of the
invasiveness of the fungus and does not reflect colonisa-
tion of a preexisting cavity, distinguishing CPNA from
aspergilloma [5,11]. The cavities that develop in CPNA
frequently contain ball like collections similar to aspergil-
lomas, but is preferable to use the term [11]. Spread may
be to the entire lung, chest wall or mediastinum [8]. Radi-
ological findings in this case consisted of an irregular,
thick-walled cavity in the right upper lobe, a mass with
soft-tissue attenuation within it, thickening of adjacent
pleura and bronchial wall thickening associated with a
'tree-in-bud' pattern.
Treatment outcome is likely to be influenced by the rapid-
ity of the therapy beginning. Amphotericin B and itraco-
nazole have been used with success in several cases of
CPNA, however new azole antifungal drugs such as vori-
conazole, posaconazole and ravuconazole have a broad
spectrum of activity and are an alternative to Aspergillus
(A) Computed tomography (CT) scan at level of upper lobes showing a thick-walled cavity with irregularity of its inner contour in the right upper lobeFigure 2
(A) Computed tomography (CT) scan at level of upper lobes showing a thick-walled cavity with irregularity of 
its inner contour in the right upper lobe. (B) CT scan at the subcarinal level, showing air-space nodules, tree-in-bud pat-
tern and consolidation at the periphery of the right lung. Fissural thickening and bronchial wall thickening and irregularity. 
Observe also small nodules in the left lung. (C and D) CT scans obtained at the same level as (A and B) two months after 
showing substantial improvement of the appearance of the lesions, persisting a thin-walled cavity in the right upper lobe and 
scattered small nodules in the lungs.Page 3 of 4
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species resistant to amphotericin B [3,13,14]. Voricona-
zole was the treatment of choice because it can be orally
administered and it has been used with success in some
series of patients. Surgical resection is reserved for patients
with hemoptysis, for those who are not tolerating antifun-
gal agents, and patients with residual localised but active
disease despite adequate antifungal therapy [5,10,15].
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